Human TLR-2 Impairs Immune Activation by Heterozygous Arg753Gln Polymorphism of

[1]  S. Khoury,et al.  Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.

[2]  R. Weissleder,et al.  Murine B16 Melanomas Expressing High Levels of the Chemokine Stromal-Derived Factor-1/CXCL12 Induce Tumor-Specific T Cell Chemorepulsion and Escape from Immune Control1 , 2006, The Journal of Immunology.

[3]  S. Ju,et al.  A Major Lung CD103 (αE)-β7 Integrin-Positive Epithelial Dendritic Cell Population Expressing Langerin and Tight Junction Proteins1 , 2006, The Journal of Immunology.

[4]  C. Knudson,et al.  The Role of Low Molecular Weight Thiols in T Lymphocyte Proliferation and IL-2 Secretion1 , 2005, The Journal of Immunology.

[5]  U. Göbel,et al.  Heterozygous Arg753Gln Polymorphism of Human TLR-2 Impairs Immune Activation by Borrelia burgdorferi and Protects from Late Stage Lyme Disease1 , 2005, The Journal of Immunology.

[6]  U. Göbel,et al.  Chronic periodontal disease is associated with single-nucleotide polymorphisms of the human TLR-4 gene , 2005, Genes and Immunity.

[7]  S. Anker,et al.  A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis , 2005, Journal of Molecular Medicine.

[8]  R. Schumann,et al.  Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. , 2005, The Lancet. Infectious diseases.

[9]  D. Malhotra,et al.  TLR2 Arg677Trp polymorphism in leprosy: revisited , 2005, Human Genetics.

[10]  N. Day,et al.  Lack of Association between Toll-Like Receptor 2 Polymorphisms and Susceptibility to Severe Disease Caused by Staphylococcus aureus , 2004, Clinical Diagnostic Laboratory Immunology.

[11]  K. Narayan,et al.  Genotype determines phenotype in experimental Lyme borreliosis , 2004, Annals of neurology.

[12]  U. Göbel,et al.  Lipopolysaccharide Binding Protein Binds to Triacylated and Diacylated Lipopeptides and Mediates Innate Immune Responses1 , 2004, The Journal of Immunology.

[13]  S. Akira,et al.  MyD88 Plays a Unique Role in Host Defense but Not Arthritis Development in Lyme Disease1 , 2004, The Journal of Immunology.

[14]  Ruth R. Montgomery,et al.  Myeloid Differentiation Antigen 88 Deficiency Impairs Pathogen Clearance but Does Not Alter Inflammation in Borrelia burgdorferi-Infected Mice , 2004, Infection and Immunity.

[15]  M. Barbouche,et al.  Toll-Like Receptor 2 Arg677Trp Polymorphism Is Associated with Susceptibility to Tuberculosis in Tunisian Patients , 2004, Clinical Diagnostic Laboratory Immunology.

[16]  G. Pasterkamp,et al.  Role of Toll‐like receptor 4 in the initiation and progression of atherosclerotic disease , 2004, European journal of clinical investigation.

[17]  A. Steere,et al.  The emergence of Lyme disease. , 2004, The Journal of clinical investigation.

[18]  T. Hartung,et al.  Heterozygous Toll-Like Receptor 2 Polymorphism Does Not Affect Lipoteichoic Acid-Induced Chemokine and Inflammatory Responses , 2004, Infection and Immunity.

[19]  A. Steere,et al.  Elucidation of Lyme arthritis , 2004, Nature Reviews Immunology.

[20]  B. Yoldaş,et al.  The Arg753Gln polymorphism of the human Toll-like receptor 2 gene in tuberculosis disease , 2004, European Respiratory Journal.

[21]  Guiqing Wang,et al.  Impaired host defense to infection and Toll-like receptor 2-independent killing of Borrelia burgdorferi clinical isolates in TLR2-deficient C3H/HeJ mice. , 2004, FEMS microbiology letters.

[22]  T. Hartung,et al.  Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. , 2003, The Journal of infectious diseases.

[23]  T. Hartung,et al.  Determination of the eicosanoid response to inflammatory stimuli in whole blood and its pharmacological modulation ex vivo. , 2003, Journal of immunological methods.

[24]  U. Göbel,et al.  Lipoteichoic Acid (LTA) of Streptococcus pneumoniaeand Staphylococcus aureus Activates Immune Cells via Toll-like Receptor (TLR)-2, Lipopolysaccharide-binding Protein (LBP), and CD14, whereas TLR-4 and MD-2 Are Not Involved* , 2003, The Journal of Biological Chemistry.

[25]  T. Hartung,et al.  A model of human whole blood lymphokine release for in vitro and ex vivo use. , 2003, Journal of immunological methods.

[26]  N. Reiner,et al.  The 19-kDa Mycobacterium tuberculosis Protein Induces Macrophage Apoptosis Through Toll-Like Receptor-21 , 2003, The Journal of Immunology.

[27]  O. Takeuchi,et al.  Differential recognition of structural details of bacterial lipopeptides by toll‐like receptors , 2002 .

[28]  S. Calvano,et al.  Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. , 2002, The Journal of infectious diseases.

[29]  D. Schwartz,et al.  Toll-like receptor 4 polymorphisms and atherogenesis. , 2002, The New England journal of medicine.

[30]  E. Fikrig,et al.  Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice , 2002, Nature Medicine.

[31]  R. M. Wooten,et al.  Toll-Like Receptor 2 Is Required for Innate, But Not Acquired, Host Defense to Borrelia burgdorferi1 , 2002, The Journal of Immunology.

[32]  T. Kang,et al.  Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. , 2001, FEMS immunology and medical microbiology.

[33]  R. M. Wooten,et al.  Host-pathogen interactions promoting inflammatory Lyme arthritis: use of mouse models for dissection of disease processes. , 2001, Current opinion in microbiology.

[34]  T. Hartung,et al.  Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. , 2001 .

[35]  A. Aderem,et al.  The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Mira,et al.  A Novel Polymorphism in the Toll-Like Receptor 2 Gene and Its Potential Association with Staphylococcal Infection , 2000, Infection and Immunity.

[37]  D. Schwartz,et al.  TLR4 mutations are associated with endotoxin hyporesponsiveness in humans , 2000, Nature Genetics.

[38]  D. Golenbock,et al.  Toll-like Receptor 2 Functions as a Pattern Recognition Receptor for Diverse Bacterial Products* , 1999, The Journal of Biological Chemistry.

[39]  R. M. Wooten,et al.  Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. , 1999, Journal of immunology.

[40]  B. Bloom,et al.  Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. , 1999, Science.

[41]  A. Steere,et al.  Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. , 1998, Science.

[42]  V. Fingerle,et al.  Immunological and molecular variability of OspA and OspC. implications forBorrelia vaccine development , 1996, Infection.

[43]  J. Benach,et al.  Lyme neuroborreliosis , 1995, Annals of neurology.

[44]  T. Hartung,et al.  Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. , 1995, Blood.

[45]  J. Weis,et al.  Borrelia burgdorferi outer surface lipoproteins OspA and OspB possess B-cell mitogenic and cytokine-stimulatory properties , 1993, Infection and immunity.

[46]  K. Weber.  Aspects of Lyme Borreliosis in Europe , 2001, European Journal of Clinical Microbiology and Infectious Diseases.